Stock Events

Stock Events

Madrigal Pharmaceuticals 

$459.81
75
-$0.20-0.04%Thursday 20:00
+$1.88+0.41%Thursday 23:30After hours

Statistics

Day High
460.31
Day Low
459.3
52W High
615
52W Low
393.61
Volume
9,708
Avg. Volume
-
Mkt Cap
10.62B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Oct 29Expected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-5.08
-3.66
-2.25
-0.83
Expected EPS
-0.834459
Actual EPS
N/A

Financials

-30.08%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
958.4MRevenue
-288.28MNet Income

Analyst Ratings

$678.80Average Price Target
The highest estimate is ⁦962.00⁩.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
90%
Hold
10%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MDGL. It's not an investment recommendation.
Microsoft
22
MSFT
NVIDIA
17
NVDA
AMD
16
AMD
Meta Platforms
16
META

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Viking Therapeutics
VKTX
Mkt Cap3.76B
Viking Therapeutics is developing therapies for metabolic and endocrine disorders, directly competing with Madrigal's NASH treatments.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences has a strong focus on liver diseases, including NASH, positioning it as a competitor in the same therapeutic area as Madrigal.
Eocene
GLMD
Mkt Cap4.14M
Galmed Pharmaceuticals is developing treatments for liver diseases, including NASH, making it a direct competitor to Madrigal.
Agios Pharmaceuticals
AGIO
Mkt Cap1.9B
Agios Pharmaceuticals focuses on metabolic disorders, competing in the same space as Madrigal's treatments for liver diseases.
Axsome Therapeutics
AXSM
Mkt Cap9.39B
Axsome Therapeutics, while primarily focused on CNS disorders, has interests in metabolic disorders, potentially putting it in competition with Madrigal.
Novartis
NVS
Mkt Cap268B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for liver diseases, making it a potential competitor to Madrigal in the NASH space.

About

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Show More
CEO
William J. Sibold
Employees
915
Country
United States
ISIN
US5588681057
WKN
000A2APCZ

Listings

MI
IT
1MDGL.MI
XETRA
DE
YDO1.XETRA
STU
DE
YDO1.STU
LSE
GB
0JXI.LSE

0 Comments

Share your thoughts

FAQs

What is Madrigal Pharmaceuticals stock price today?▼
The current price of MDGL is $459.81 USD — it has decreased by -0.04% in the past 24 hours. Watch Madrigal Pharmaceuticals stock price performance more closely on the chart.
What is Madrigal Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Madrigal Pharmaceuticals stocks are traded under the ticker MDGL.
Is Madrigal Pharmaceuticals stock price growing?▼
MDGL stock has fallen by -2.53% compared to the previous week, the month change is a -13.09% fall, over the last year Madrigal Pharmaceuticals has showed a +4% increase.
What is Madrigal Pharmaceuticals market cap?▼
Today Madrigal Pharmaceuticals has the market capitalization of 10.62B
When is the next Madrigal Pharmaceuticals earnings date?▼
Madrigal Pharmaceuticals is going to release the next earnings report on October 29, 2026.
What were Madrigal Pharmaceuticals earnings last quarter?▼
MDGL earnings for the last quarter are -1.99 USD per share, whereas the estimation was -2.68 USD resulting in a +25.65% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Madrigal Pharmaceuticals revenue for the last year?▼
Madrigal Pharmaceuticals revenue for the last year amounts to 958.4M USD.
What is Madrigal Pharmaceuticals net income for the last year?▼
MDGL net income for the last year is -288.28M USD.
How many employees does Madrigal Pharmaceuticals have?▼
As of October 16, 2026, the company has 915 employees.
In which sector is Madrigal Pharmaceuticals located?▼
Madrigal Pharmaceuticals operates in the Health & Wellness sector.
When did Madrigal Pharmaceuticals complete a stock split?▼
The last stock split for Madrigal Pharmaceuticals was on July 25, 2016 with a ratio of 1:35.
Where is Madrigal Pharmaceuticals headquartered?▼
Madrigal Pharmaceuticals is headquartered in WEST CONSHOHOCKEN, United States.